Compare Enveric Biosciences Inc (ENVB) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Ryanair Holdings plc — how do they compare? Enveric Biosciences Inc trades at $1.43 (market cap $5.32M), while Ryanair Holdings plc trades at $66.16 (market cap $31.83B). The key difference: Ryanair Holdings plc is far larger — about 5983.1× Enveric Biosciences Inc's market cap, and Ryanair Holdings plc pays a 1.48% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | RYAAY | |
|---|---|---|
Market Cap | $5.32M | $31.83B |
Sector | Health | Industrials |
52-Week High | $17.40 | $73.82 |
52-Week Low | $1.28 | $53.24 |
Enterprise Value | $408.82K | $29.49B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
RYAAY trades at $66.29, up 3.11% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 14.32, net income margin of 13.98%, and consistent earnings beats. Recent news highlights passenger growth and operational updates, though a window incident adds scrutiny. Cash flow remains positive from operations at $3.42B despite negative net cash flow.
Outlook is positive with analyst consensus at 62.5% buy ratings. Revenue growth to $15.5B projected for 2026 supports upside, but risks include fuel cost volatility and regulatory pressures. The stock's valuation and profitability metrics present an attractive entry for long-term investors amid sector recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
